TELETRADER News
10/28, 12:31 PM (Source: TeleTrader)
more TeleTrader news

Merck+0.19%

212.90
Chart for: MERCK KGAA O.N.

Merck's Q3 revenue rises to $13.2B after 20% jump

American pharmaceutical company Merck & Co., Inc. noted on Thursday that its third-quarter revenue soared 20% to $13.2 billion, surpassing the market estimates.

Meanwhile, earnings per share during the same period reached $1.8, marking a 96% surge compared to the prior year's third quarter, while the company's net income jumped 97% on an annual basis to $4.57 billion. Sales of the firm's flagship Keytruda and Gardasil drugs jumped 22% and 68% to come in at $4.5 billion and $2 billion, respectively.

"We achieved notable clinical milestones in the key areas of oncology and COVID-19, including positive Phase 3 results for molnupiravir. We recently announced our proposed acquisition of Acceleron, which will strengthen our cardiovascular portfolio with complementary, cutting-edge science and an exciting late-stage candidate," CEO Rob Davis stated.

Merck shares rose almost 1% in the premarket after the release.

Breaking the News / BU